OpenAI Rules Out 2026 IPO as Altman Prioritizes AI Safety 
UK Businesses Urge Government to Cut Electricity Levies 
Asian Tech Stocks Slide as AI Concerns and Rising Bond Yields Hit Chipmakers 
Gold Prices Steady as Oil Disruptions Boost Fed Rate Hike Bets 
Anthropic Eyes Second Straight Profitable Quarter Ahead of Potential IPO 
Asian Bank Stocks Slide as BofA Warning and Rising Yields Hit Sentiment 
Optus Apologises After Network Outage Disrupts Emergency Calls 
Ares Names James Garforth Principal for Asia Direct Lending 
SoftBank Shares Jump 8% as SB Energy IPO Optimism Builds 
China Industrial Output Beats Forecasts as Exports Support Growth 
Goldman Sachs Forecasts Fed Rate Hike as Inflation Risks Rise 
Ex-Google DeepMind Researcher Warns AI Could Pose Existential Threat 
Enflame Shares Surge 200% in Shanghai AI Chip Debut 
Houthis Escalate Saudi Attacks as Red Sea Oil Risks Grow 
BOJ Set to Raise Rates to 1.25% as Inflation Risks Build 
China Home Prices Fall Again as Property Slump Drags on Growth 
Add as a preferred source on Google
South Korean drugmaker Daewoong Pharmaceutical Co. inked a US$430 million deal to provide US pharmaceutical venture firm Neurogastrx Inc. with its technology for fexuprazan, the novel drug candidate for gastroesophageal reflux.
The technology deal with Neurogastrx made the US the fourth country that the South Korean firm has signed technology deals with, after China, Brazil, and Mexico.
The said countries account for almost 40 percent of the global gastrointestinal disorder market.
The combined value of the deals is already over 1 trillion won.
Daewoong Pharmaceutical will also receive 13.5 percent of Neurogastrx's shares.
Daewoong Pharmaceutical claims that fexuprazan, a class of potassium-competitive acid blockers, exhibited a cure rate of 99 percent during the phase three clinical trials and is expected to win approval from local drug authorities soon.
Neurogastrx is a privately-held biopharmaceutical company that develops therapies for gastrointestinal disorders.
